$CPIX
CUMBERLAND PHARMACEUTICALS INC Stock $cpix

$cpix Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000162828024022658 Filed on May 10, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$9.849M	$8.498M
YoY Change	-9.55%	-7.88%
Cost Of Revenue	$1.711M	$1.576M
YoY Change	12.5%	26.02%
Gross Profit	$8.138M	$6.922M
YoY Change	-13.13%	-13.19%
Gross Profit Margin	82.63%	81.46%
Selling, General & Admin	$7.006M	$6.522M
YoY Change	-0.52%	-3.75%
% of Gross Profit	86.09%	94.23%
Research & Development	$1.059M	$1.158M
YoY Change	-7.5%	-22.77%
% of Gross Profit	13.02%	16.73%
Depreciation & Amortization	$1.139M	$1.151M
YoY Change	-5.12%	-8.36%
% of Gross Profit	14.0%	16.62%
Operating Expenses	$8.065M	$7.681M
YoY Change	-1.49%	-7.19%
Operating Profit	-$1.027M	-$1.869M
YoY Change	-4591.4%	22.04%
Interest Expense	$126.3K	$118.5K
YoY Change	-34.41%	-36.4%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Pretax Income	-$1.091M	-$1.891M
YoY Change	-225.56%	-1155.12%
Income Tax	$11.44K	$11.44K
% Of Pretax Income
Net Earnings	-$1.086M	-$1.946M
YoY Change	-224.47%	-1112.71%
Net Earnings / Revenue	-11.02%	-22.9%
Basic Earnings Per Share	-$0.08	-$0.14
Diluted Earnings Per Share	-$0.08	-$0.14
COMMON SHARES
Basic Shares Outstanding	14.19M shares	14.18M shares
Diluted Shares Outstanding	14.12M shares	14.10M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.34M	$18.55M
YoY Change	-5.0%	13.2%
Cash & Equivalents	$17.34M	$18.55M
Short-Term Investments
Other Short-Term Assets	$2.323M	$2.683M
YoY Change	1.97%	-1.21%
Inventory	$4.302M	$4.328M
Prepaid Expenses
Receivables	$11.62M	$10.65M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$35.58M	$36.21M
YoY Change	-18.53%	-17.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$337.1K	$369.5K
YoY Change	-12.3%	4.13%
Goodwill	$914.0K	$914.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.994M	$3.061M
YoY Change	14.84%	20.24%
Total Long-Term Assets	$42.94M	$45.30M
YoY Change	-6.05%	-0.78%
TOTAL ASSETS
Total Short-Term Assets	$35.58M	$36.21M
Total Long-Term Assets	$42.94M	$45.30M
Total Assets	$78.52M	$81.51M
YoY Change	-12.15%	-8.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.51M	$13.08M
YoY Change	14.63%	16.52%
Accrued Expenses	$376.8K	$362.2K
YoY Change	17.44%	128.73%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$24.76M	$26.43M
YoY Change	-8.17%	2.79%
LONG-TERM LIABILITIES
Long-Term Debt	$16.09M	$16.08M
YoY Change	22.39%	0.07%
Other Long-Term Liabilities	$6.539M	$6.610M
YoY Change	-5.97%	-6.78%
Total Long-Term Liabilities	$6.539M	$6.610M
YoY Change	-5.97%	-6.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.76M	$26.43M
Total Long-Term Liabilities	$6.539M	$6.610M
Total Liabilities	$52.49M	$54.32M
YoY Change	-0.1%	1.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$20.52M	-$19.43M
YoY Change	102.28%	76.41%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$26.35M	$27.49M
YoY Change
Total Liabilities & Shareholders Equity	$78.52M	$81.51M
YoY Change	-12.15%	-8.9%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$1.086M	-$1.946M
YoY Change	-224.47%	-1112.71%
Depreciation, Depletion And Amortization	$1.139M	$1.151M
YoY Change	-5.12%	-8.36%
Cash From Operating Activities	-$855.7K	-$2.137M
YoY Change	-116.34%	50.66%
INVESTING ACTIVITIES
Capital Expenditures	$46.80K	$41.62K
YoY Change	-51.66%	-61.2%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$46.80K	-$58.19K
YoY Change	-51.66%	-66.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-309.6K	$2.422M
YoY Change	-90.55%	-236.12%
NET CHANGE
Cash From Operating Activities	-855.7K	-$2.137M
Cash From Investing Activities	-46.80K	-$58.19K
Cash From Financing Activities	-309.6K	$2.422M
Net Change In Cash	-1.212M	$226.9K
YoY Change	-165.06%	-106.73%
FREE CASH FLOW
Cash From Operating Activities	-$855.7K	-$2.137M
Capital Expenditures	$46.80K	$41.62K
Free Cash Flow	-$902.5K	-$2.178M
YoY Change	-117.56%	42.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Line Of Credit Facility Expiration Period LineOfCreditFacilityExpirationPeriod	P3Y
CY2023Q3	us-gaap	Debt Instrument Variable Interest Rate Type Extensible Enumeration DebtInstrumentVariableInterestRateTypeExtensibleEnumeration	http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1575542	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1250264	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4154588	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4277318	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1158253	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1499670	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2367907	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2498993	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1110661	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1230071	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	10366951	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	10756316	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1869250	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1531678	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	96746	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	50190	usd
CY2024Q1	us-gaap	Other Income OtherIncome	0	usd
CY2023Q1	us-gaap	Other Income OtherIncome	1847065	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	118526	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	186353	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1891030	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	179224	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11442	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6938	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-1902472	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	172286	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	43791	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-19898	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1946263	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	192184	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14098022	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14359322	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14098022	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14587843	shares
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-1902472	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	172286	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1150685	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	29259869	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	78754	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1255675	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	285184	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	172209	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	78754	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	90156	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-230430	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-267637	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3810	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	4296	usd
CY2024Q1	us-gaap	Insured Event Gain Loss InsuredEventGainLoss	0	usd
CY2023Q1	us-gaap	Insured Event Gain Loss InsuredEventGainLoss	1847065	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1066410	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-481613	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-170469	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	323557	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-205619	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-383612	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-213825	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	127137	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-645542	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1105263	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	156728	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-530872	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2136647	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1418209	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	41621	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	107260	usd
CY2024Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	16565	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	67193	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-58186	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-174453	usd
CY2024Q1	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	11000000	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	8000000	usd
CY2024Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7700000	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	8127714	usd
CY2024Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	630701	usd
CY2023Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1464311	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	247605	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	187117	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2421694	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1779142	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	226861	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3371804	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18321624	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19757970	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18548485	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16386166	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	35974006	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	90156	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	187961	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	172286	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36048487	usd
CY2024Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	246599	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-1902472	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	27189552	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div>
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1946263	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	192184	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14098022	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14359322	shares
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	228521	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14098022	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14587843	shares
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	496859	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	331338	shares
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8497701	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9224638	usd
CY2024Q1	us-gaap	Sublease Income SubleaseIncome	200000	usd
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	100000	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2024Q1	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	12772140	usd
CY2023Q4	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	12619092	usd
CY2024Q1	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	231264	usd
CY2023Q4	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	149701	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4240018	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4645098	usd
CY2024Q1	us-gaap	Inventory Gross InventoryGross	17243422	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	17413891	usd
CY2024Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	12915896	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	12804529	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	4327526	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	4609362	usd
CY2024Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	12915896	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	12804529	usd
CY2021Q4	cpix	Lessee Operating Lease Rent Increase LesseeOperatingLeaseRentIncrease	0.025
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6521088	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6674394	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	362244	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	348092	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5200148	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5296247	usd
CY2024Q1	cpix	Lease Liability LeaseLiability	5562392	usd
CY2023Q4	cpix	Lease Liability LeaseLiability	5644339	usd
CY2024Q1	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	200000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	649494	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	836100	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	909911	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	934180	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	740791	usd
CY2024Q1	cpix	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	4847401	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8917877	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3355485	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	5562392	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	355064	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	234863	usd
CY2024Q1	us-gaap	Sublease Income SubleaseIncome	155683	usd
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	115631	usd
CY2024Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	2800000	usd
CY2017Q4	cpix	Stock Issued During Period Shelf Registration Proceeds From Sale Of Corporate Securities StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities	100000000	usd
CY2024Q1	cpix	Stock Issued During Period Shelf Registration Proceeds From Sale Of Corporate Securities StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities	5800000	usd
CY2024Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	44100000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-022658-index-headers.html	Edgar Link	pending
0001628280-24-022658-index.html	Edgar Link	pending
0001628280-24-022658.txt	Edgar Link	pending
0001628280-24-022658-xbrl.zip	Edgar Link	pending
a2024q1-exhibit106.htm	Edgar Link	pending
a2024q1-exhibit311.htm	Edgar Link	pending
a2024q1-exhibit312.htm	Edgar Link	pending
a2024q1-exhibit321.htm	Edgar Link	pending
cpix-20240331.htm	Edgar Link	pending
cpix-20240331.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
cpix-20240331_cal.xml	Edgar Link	unprocessable
cpix-20240331_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cpix-20240331_lab.xml	Edgar Link	unprocessable
cpix-20240331_pre.xml	Edgar Link	unprocessable
cpix-20240331_htm.xml	Edgar Link	completed
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CPIX
CUMBERLAND PHARMACEUTICALS INC Stock $cpix

2024 Q2 Form 10-Q Financial Statement

#000162828024022658 Filed on May 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPIX CUMBERLAND PHARMACEUTICALS INC Stock $cpix

2024 Q2 Form 10-Q Financial Statement

#000162828024022658 Filed on May 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPIX
CUMBERLAND PHARMACEUTICALS INC Stock $cpix